BR112021002734A2 - tratamento de linfoma folicular reincidente - Google Patents
tratamento de linfoma folicular reincidente Download PDFInfo
- Publication number
- BR112021002734A2 BR112021002734A2 BR112021002734-3A BR112021002734A BR112021002734A2 BR 112021002734 A2 BR112021002734 A2 BR 112021002734A2 BR 112021002734 A BR112021002734 A BR 112021002734A BR 112021002734 A2 BR112021002734 A2 BR 112021002734A2
- Authority
- BR
- Brazil
- Prior art keywords
- nr1br1c
- compound
- mixture
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718926P | 2018-08-14 | 2018-08-14 | |
| US62/718,926 | 2018-08-14 | ||
| US201962836507P | 2019-04-19 | 2019-04-19 | |
| US62/836,507 | 2019-04-19 | ||
| PCT/US2019/046408 WO2020036997A1 (en) | 2018-08-14 | 2019-08-13 | Treatment of relapsed follicular lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021002734A2 true BR112021002734A2 (pt) | 2021-07-20 |
Family
ID=69525835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021002734-3A BR112021002734A2 (pt) | 2018-08-14 | 2019-08-13 | tratamento de linfoma folicular reincidente |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210196725A1 (https=) |
| EP (1) | EP3836936A4 (https=) |
| JP (1) | JP2021534116A (https=) |
| KR (1) | KR20210043637A (https=) |
| CN (1) | CN112839659A (https=) |
| AU (1) | AU2019321526A1 (https=) |
| BR (1) | BR112021002734A2 (https=) |
| CA (1) | CA3109377A1 (https=) |
| IL (1) | IL280721A (https=) |
| MA (1) | MA53237A (https=) |
| MX (1) | MX2021001765A (https=) |
| SG (1) | SG11202101417XA (https=) |
| TW (1) | TW202021593A (https=) |
| WO (1) | WO2020036997A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI572599B (zh) | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| KR20200041358A (ko) | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2919869B1 (fr) * | 2007-08-09 | 2009-09-25 | Sanofi Aventis Sa | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| TWI572599B (zh) * | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| AU2013299627C1 (en) * | 2012-08-09 | 2018-05-31 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| MA38462A1 (fr) * | 2013-04-08 | 2017-10-31 | Bayer Pharma AG | Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes |
| HUE049175T2 (hu) * | 2014-09-23 | 2020-09-28 | Hoffmann La Roche | Eljárás anti-CD79b immunkonjugátumok alkalmazására |
| IL292938A (en) * | 2016-09-19 | 2022-07-01 | Mei Pharma Inc | Combined treatment |
| KR20200041358A (ko) * | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
-
2019
- 2019-08-13 BR BR112021002734-3A patent/BR112021002734A2/pt not_active IP Right Cessation
- 2019-08-13 EP EP19849643.2A patent/EP3836936A4/en not_active Withdrawn
- 2019-08-13 WO PCT/US2019/046408 patent/WO2020036997A1/en not_active Ceased
- 2019-08-13 SG SG11202101417XA patent/SG11202101417XA/en unknown
- 2019-08-13 CN CN201980067638.8A patent/CN112839659A/zh active Pending
- 2019-08-13 AU AU2019321526A patent/AU2019321526A1/en not_active Abandoned
- 2019-08-13 MX MX2021001765A patent/MX2021001765A/es unknown
- 2019-08-13 JP JP2021506718A patent/JP2021534116A/ja active Pending
- 2019-08-13 KR KR1020217007422A patent/KR20210043637A/ko not_active Ceased
- 2019-08-13 CA CA3109377A patent/CA3109377A1/en active Pending
- 2019-08-13 US US17/268,050 patent/US20210196725A1/en not_active Abandoned
- 2019-08-13 MA MA053237A patent/MA53237A/fr unknown
- 2019-08-14 TW TW108128971A patent/TW202021593A/zh unknown
-
2021
- 2021-02-08 IL IL280721A patent/IL280721A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3109377A1 (en) | 2020-02-20 |
| SG11202101417XA (en) | 2021-03-30 |
| AU2019321526A1 (en) | 2021-03-25 |
| CN112839659A (zh) | 2021-05-25 |
| WO2020036997A1 (en) | 2020-02-20 |
| KR20210043637A (ko) | 2021-04-21 |
| JP2021534116A (ja) | 2021-12-09 |
| EP3836936A4 (en) | 2022-05-18 |
| EP3836936A1 (en) | 2021-06-23 |
| US20210196725A1 (en) | 2021-07-01 |
| TW202021593A (zh) | 2020-06-16 |
| IL280721A (en) | 2021-03-25 |
| MA53237A (fr) | 2021-06-23 |
| MX2021001765A (es) | 2021-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10080756B2 (en) | Combination methods for treating cancers | |
| JP2021517116A (ja) | 併用療法 | |
| US11351176B2 (en) | Combination therapy | |
| TW202545942A (zh) | Ｃｄｋ抑制劑 | |
| TW201521725A (zh) | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 | |
| BR112021002734A2 (pt) | tratamento de linfoma folicular reincidente | |
| JP7234418B2 (ja) | Ｂｒａｆｖ６００ｅ大腸癌の治療に使用するためのｅｒｋ１／２阻害剤と、ｂｒａｆ阻害剤およびｅｇｆｒ阻害剤との三重組み合わせ | |
| BR112021002760A2 (pt) | tratamento de malignidades de célula b | |
| JP2021534114A (ja) | 併用療法 | |
| WO2023070120A1 (en) | Ketoamides for treating malignancy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2787 DE 04-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |